Your browser doesn't support javascript.
loading
Adverse events of anti-tumour necrosis factor therapy for ankylosing spondylitis: a retrospective study of 369 Chinese Han population / 中华风湿病学杂志
Chinese Journal of Rheumatology ; (12): 785-788, 2011.
Article in Zh | WPRIM | ID: wpr-423089
Responsible library: WPRO
ABSTRACT
ObjectiveTo evaluate the adverse events occurred during tumour necrosis factor (TNF)-αblocker treatment in Chinese Han population patients with ankylosing spondylitis (AS).MethodsThis study had enrolled 369 Chinese Han population patients with ankylosing spondylitis.They all received TNF-αblocker treatment in the hospital.All 1011 administration were recorded in total.All of them were evaluated for adverse events 2 hours after injection,126 of them had received long-term TNF-α blocker injection,and they were followed-up at week 8,12,52,104.Mild immediate adverse events and long-term adverse events were all counted.SPSS 10.0 software package was used for Fisher's exact test.ResultsThree hundred and sixty-nine patients had 1011 administrations in total,652 had received rhTNFR:Fc,316 had infliximab,21had etanercept,22 had adalimumab injections.Adverse events 2 hours after injection were:17 (2.6%) for rhTNFR:Fc,12 (3.8%) for infliximab,0 for etanercept,1 (4.5%) for adalimumab.Twenty adverse events were mild(12 for rhTNFR:Fc,9 for infliximab),5 events were moderate(3 for rhTNFR:Fc,1 for infliximab,1 for adalimumab),4 events were severe(2 for rhTNFR:Fc,2 for infliximab).The frequency of adverse events were comparable between rhTNFR:Fc and Infliximab injection in immediate adverse reactions (P=0.31).One hundred and twenty-six (69 rhTNFR:Fc,57 infliximab) patients had long-term usage,and were followed-up at week 8,12,52,104,39 patients had adverse reactions:20 (51.3%) for rhTNFR:Fc,19(48.7%) for infliximab.Thirty-seven patients had infectious events(94.9% ),1 neurological event(2.6%),and 1 patient had tuberculosis relapse (2.6%).Outcomes were comparable with rhTNFR:Fc and infliximab in long-term usage(P=0.69).ConclusionAttention should be paid to the above events in Chinese Han patients with ankylosing spondylitis who were treated with TNF-α blocker treatment.Special attention should be paid to those patients who are in their third or fourth injection.The occurrence of immediate reaction or long-term adverse events between rhTNFR:Fc and infliximab are comparable.
Key words
Full text: 1 Index: WPRIM Type of study: Observational_studies Language: Zh Journal: Chinese Journal of Rheumatology Year: 2011 Type: Article
Full text: 1 Index: WPRIM Type of study: Observational_studies Language: Zh Journal: Chinese Journal of Rheumatology Year: 2011 Type: Article